Phathom Pharmaceuticals, Inc. (PHAT)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Phathom Pharmaceuticals, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 9, 2026 | 5.27 | 5.49 | 5.18 | 5.23 | 18,393 |
| Nov 6, 2026 | 5.26 | 5.30 | 5.04 | 5.25 | 1,770,849 |
| Nov 5, 2026 | 5.70 | 5.71 | 5.04 | 5.08 | 1,552,395 |
| Nov 4, 2026 | 5.95 | 6.13 | 5.66 | 5.68 | 1,514,099 |
| Nov 3, 2026 | 5.92 | 6.11 | 5.50 | 5.74 | 2,162,820 |
| Nov 2, 2026 | 5.76 | 5.92 | 5.50 | 5.92 | 2,812,513 |
| Oct 30, 2026 | 6.32 | 6.32 | 5.59 | 5.74 | 1,620,581 |
| Oct 29, 2026 | 7.00 | 7.00 | 5.71 | 6.22 | 3,843,453 |
| Oct 28, 2026 | 5.94 | 6.43 | 5.85 | 6.28 | 2,082,825 |
| Oct 27, 2026 | 5.91 | 6.18 | 5.81 | 5.99 | 2,104,010 |
| Oct 26, 2026 | 5.70 | 6.06 | 5.70 | 5.94 | 2,113,849 |
| Oct 23, 2026 | 6.72 | 6.76 | 5.01 | 5.74 | 4,868,225 |
| Oct 22, 2026 | 7.04 | 7.22 | 6.96 | 7.01 | 811,715 |
| Oct 21, 2026 | 7.31 | 7.48 | 7.01 | 7.03 | 784,175 |
| Oct 20, 2026 | 7.04 | 7.40 | 6.96 | 7.31 | 724,325 |
| Oct 19, 2026 | 6.88 | 7.05 | 6.78 | 7.01 | 1,017,112 |
| Oct 16, 2026 | 7.51 | 7.57 | 6.90 | 6.92 | 1,254,291 |
| Oct 15, 2026 | 7.54 | 7.69 | 7.41 | 7.50 | 1,210,198 |
| Oct 14, 2026 | 6.97 | 7.72 | 6.92 | 7.40 | 1,721,072 |
| Oct 13, 2026 | 7.14 | 7.16 | 6.86 | 7.00 | 1,947,160 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Narula Sanjeev | Chief Financial & Bus. Officer | Automatic Sell | 13.5K | $91.4K | Oct 6, 2026 |
 Breedlove Robert Charles | Principal Accounting Officer | Automatic Sell | 460 | $4.2K | Sep 3, 2026 |
| Breedlove Robert Charles | Principal Accounting Officer | Automatic Sell | 1.6K | $17.2K | Jul 14, 2026 |
 Parikh Asit | Director | Withholding/Transfer | 28.0K | -- | May 22, 2026 |
| Parikh Asit | Director | Withholding/Transfer | 28.0K | -- | May 22, 2026 |
| Parikh Asit | Director | Option Exercise | 17.5K | $86.6K | May 20, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Frazier Life Sciences Management, L.P. | 12.5M | 15.3% | 13F |
Medicxi Ventures Management Ltd | 7.5M | 9.2% | 13F |
James N. Topper · joint filing· may incl. warrants· filed Nov 2026 | 6.0M | 7.4% | 13D |
BlackRock, Inc. | 4.5M | 5.6% | 13F |
Invesco Ltd. | 4.0M | 5.0% | 13F |
Medicxi Growth I LP · may incl. warrants· reaffirmed 13F Nov 2026 | 3.7M | 4.5% | 13G |
Carlyle Group Inc. | 3.5M | 4.3% | 13F |
Carlyle Group Inc. · also on 13F· may incl. warrants· filed Aug 2025 | 3.5M | 4.3% | 13G |
Millennium Management LLC · also on 13F· joint filing· may incl. warrants· filed Jul 2026 | 3.4M | 4.2% | 13G |
MILLENNIUM MANAGEMENT LLC | 3.4M | 4.2% | 13F |
Insiders
- Narula SanjeevChief Financial & Bus. Officer
- Breedlove Robert CharlesPrincipal Accounting Officer
- Parikh AsitDirector
- Topper James NDirector
- KARBE FRANKDirector
- COLA MICHAEL FDirector
- FIELDS HEIDIDirector
- Stenhouse MarkDirector
- Schroeder Theodore RDirector
- Cook Anne MarieChief Legal Off. & Corp. Sec.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
based on 81.29M shares outstanding
US30d Avg
1.85M
60d Avg
1.62M
90d Avg
1.43M